Meg Wirth is an expert in maternal and neonatal health innovation . She is the co-founder of Maternova and a S.E.VEN fellow and a Cartier Women's Initiative finalist. She has advised dozens of entrepreneurs and startups in women's health and global health. Meg has also worked as a member of the Rockefeller Foundation’s Health Equity team and co-edited a major volume called Challenging Inequities in Health: From Ethics to Action. She was a co-author of the UN Millennium Project’s final report on child and maternal health. She has a BA from Harvard University and an MPA in international development from Princeton University's Woodrow Wilson School.
Kevin Kennedy is Maternova's CFO along with acting as President of Double K Consulting Mr. Kennedy brings 20 years of experience having worked for and with a number of small businesses, trade associations, nonprofit organizations, and larger national and international corporations. The positions he has held include CFO, Treasurer, Director of Accounting, Director of Finance, Mergers & Acquisitions, Program Control Officer/Internal Auditor and Various Controllerships.
Dr. Mallon works with Maternova as Director of Revenue & Growth, along with providing clinical expertise. He founded Calista Therapeutics in 2012 based upon the discovery and development of a technology platform of therapeutics that modulate the cellular transport, location and activation of regulatory proteins. Dr Mallon is a biotech entrepreneur, specializing in the identification and creation of early stage value in promising therapeutics in diseases that have high unmet clinical need and de-risked development pathways.
Previously Dr Mallon founded Ardane Therapeutics, Inc. (USA), and Carlton Pharmaceutics (UK). Dr Mallon is an inventor on several patents based upon his discoveries in addition to several publications. Dr Mallon has a Ph.D. from the University of Glasgow, taught and undertook research at Brown University and is a registered pharmacist. Dr Mallon has served as an expert scientific reviewer for both the NIH and NSF grant committees focused upon drug development.